Introduction
Hepatitis C virus (HCV) and HIV significantly affect the morbidity and mortality of infected individuals globally [1] [2] [3] . Although HCV and HIV are both blood-borne pathogens that share similar modes of transmission, the transmission efficiency of each virus varies [4] . HCV is more than 10 times as infectious as HIV through percutaneous blood exposures, and the prevalence of HCV infection among HIV-infected persons who inject drugs (PWID) is ∼ 90% [5] . The majority of HIV/HCV coinfected individuals are former or current long-term PWID [6] .
Located in close proximity to the 'Golden Triangle' region (Laos, Myanmar, and Thailand), one of Asia's main opium-producing areas, Vietnam has a large population of PWID, ∼ 200 000 persons [7, 8] , and a high prevalence of HIV, HCV, and HIV/HCV coinfection [9] . The National HIV prevalence in Vietnam among PWID was ∼ 30% between 2007 and 2012 [10] , varying by region from 13.5 to 64% [11] . The prevalence of HCV among PWID has been reported to be as high as 74.1% in 2003 [12] . Research suggests that HCV is acquired relatively early after the initiation of injection, and the mean time between the first injection and the first positive HCV test was 1.2-2 years [13] . Similarly, a higher risk for HIV was observed early in course of injection among PWID [14] .
Percutaneous exposures cause most HCV infections [15] . Shared use of a syringe and drug preparation equipment can expose PWID to infectious blood and increase their likelihood of developing HCV and HIV infections [16] . Specific patterns of injection behaviors that increase transmission of HCV and HIV in regions need to be explored. In the urban areas of Vietnam, psychoactive substances, called 'Western medicine', have become popular among young PWID [8] . These substances, such as diazepam and novocaine, may be used to amplify, augment, or extend the positive psychoactive effects of heroin [17] , or to forestall the onset of heroin withdrawal [13] .
The context in which PWID abuse these substances and the impact that injecting these drugs has on the transmission of HIV and HCV are unknown.
HIV and HCV coinfection complicates clinical care for patients and increases the probability of morbidity and mortality as compared with monoinfection. HIV infection facilitates hepatic fibrosis in HCV-infected patients, and HCV triples the chances of liver-associated toxicity from antiretroviral therapy [18] , making it more difficult for doctors to optimize treatment strategy. Furthermore, HIV/HCV coinfection places a significant burden on the HIV/AIDS care delivery system. Despite greater associated morbidity and mortality and higher healthcare costs, HIV/HCV coinfection has received far less health investment than HIV alone, and data on how to specifically target this high-risk population for the provision of effective prevention and treatment are scarce [15] .
In this study, we estimated the prevalence of HIV, HCV, and HIV/HCV coinfection, explored their associations with lifetime injection behaviors, and compared correlates of HCV monoinfection and HIV/HCV coinfection in a population of PWID living in northeast Vietnam.
Methods

Study population
Out-of-treatment PWID were recruited by trained outreach workers, many of whom were former PWID, to participate in a cluster randomized controlled trial of a peer educator, network-oriented behavioral intervention to decrease HIV risk among PWID. The study was conducted between 2005 and 2007 in the Thai Nguyen Province, which borders China, is 50 miles from Hanoi, is the capital of Vietnam, and has a tradition of opium cultivation and use.
We analyzed data collected during the screening phase of the main HIV intervention trial. To be eligible for screening, participants had to (i) be between 18 and 45 years old, and (ii) have injected in the past 6 months. To be eligible for trial enrollment, the index participants were required to (i) be at least 18 years of age, (ii) have injected at least once a week in the past 3 months, (ii) have HIV negative antibody test results within 30 days before randomization, and (iv) be willing to identify and recruit at least one eligible network member. Network members had to (i) be at least 18 years of age, (ii) have injected drugs with or have had sexual intercourse with their index participant in the past 3 months, and (iii) have interacted at least once a week with the index participant. Network members were not required to be HIV negative. Eligible network members (index and associated network members) were randomized to either the intervention arm or the control arm (1 : 1 ratio). Details of this trial have been presented elsewhere [19] . The research protocol was reviewed and approved by the Johns Hopkins Bloomberg School of Public Health Institutional Review Board and the Thai Nguyen Center for Preventive Medicine Institutional Review Board.
Data collection
A total of 1434 consenting PWID underwent a baseline behavioral assessment interview and also underwent HIV and HCV antibody testing at baseline. The surveys were administered face-to-face, using a structured questionnaire. The survey asked about sociodemographic characteristics and lifetime injection behaviors of interest, including ever sharing a needle, ever reusing a needle and syringe, ever sharing diazepam (ever drawn diazepam from the same ampoule with other people), ever sharing novocaine (ever drawn novocaine from the same ampoule with other people), and other injection-related variables such as duration of injection drug use. The presence of tattoos and the number of sexual partners in their lifetime were also assessed.
HIV serostatus was determined using two HIV enzymelinked immunosorbent assays (Abbott Murex Biotech Ltd, Kent, England and BioRad Laboratories, Marnes-la-Coquette, France); reactive samples were confirmed by western blotting (BioRad Laboratories). To determine HCV serostatus, specimens were measured for HCV antibody using a second generation enzyme-linked immunosorbent assay (Ortho Clinical Diagnostics, Rochester, New York, USA).
The primary outcomes of interest were HCV monoinfection (defined as HCV antibody positivity alone) and HIV/HCV coinfection (defined as positivity for both HIV and HCV antibody testing). Lifetime injection behaviors were our primary variables of interest, including ever sharing a needle, ever reusing a syringe and needle, ever sharing diazepam, ever sharing novocaine, and ever sharing diazepam or novocaine.
Statistical analysis
Frequency distributions by prevalent HIV and HCV serostatuses (no HIV or HCV infection, HCV monoinfection, or HIV/HCV coinfection) were calculated to present a profile of sample characteristics.
In the univariate analysis, we estimated unadjusted odds ratios of HCV monoinfection or HIV/HCV coinfection for each demographic variable, as compared with the reference group (no HIV or HCV infection). This was done to facilitate model building in multivariate analysis. Variables with a P-value of 0.05 were entered into a multivariate model and automatically chosen by a backward stepwise selection procedure in combination with likelihood tests (two-sides, P < 0.05). Predetermined variables (including age and number of sexual partners in the lifetime) were locked into models regardless of statistical significance, considering known risk factors for HIV and HCV infections based on previous studies [9, 16, [20] [21] [22] . Demographic characteristics and risk behaviors identified through this procedure were used as the basic variables in multivariate analysis. To compare the independent association of each lifetime injection behavior of interest (ever sharing a needle, ever reusing a needle and syringe, ever sharing diazepam, and ever sharing novocaine), eight models were constructed, controlling for basic variables (Table 1 ). We used multinomial logistic regression models to simultaneously explore the correlates of HCV monoinfection and HIV/HCV coinfection.
Possible interactions in final models, on the basis of prior knowledge, were examined, such as being in a stable relationship and reusing a syringe and needle. Variance inflation factors were calculated to determine the potential colinearity among independent variables. A ratio of 1 : 10 at least for the number of explanatory variables versus sample size was applied to account for the risk of overfitting. The model fit was addressed using the Hosmer-Lemeshow goodness-of-fit test because of the large number of unique covariate patterns in our models. All data analyses were carried out using Stata statistical software, version 12.0 (Stata Corp LP, College Station, Texas, USA).
Results
Description of the study population
A total of 1434 individuals completed the baseline study visit. The median age was 31 years (interquartile range, 27-36 years). The participants were mostly male (96%). Thirty-two percent were in a stable relationship (defined as currently married or living with a partner), about half (47%) had completed high school, and most (71%) had either a full-time or a part-time job. About half (52%) had ever had a tattoo ( Table 2) . Most PWID were frequent injectors, with 95% injecting drugs at least 2-3 days per week in the past 3 months. They also had a relatively long history of injection drug use, with 95% injecting drugs for more than 2 years. Thirty-four percent reported a history of drug treatment. Twenty-eight percent had shared a needle in their lifetime, and 83% reported that they had reused a needle and syringe in their lifetime. Almost half had shared diazepam or novocaine in their lifetime (12% had shared diazepam and 46% had shared novocaine). Most participants (44%) had two to five sexual partners in their lifetime, 32% had had more than five sexual partners, and 18% had one or no sexual partner in their lifetime ( Table 2) .
Prevalence of HIV and HCV
Among all participants, 88.8% were infected with HCV and 35.1% were infected with HIV. The prevalence of HCV monoinfection was 53.9% and the prevalence of HIV/HCV coinfection was 34.8%. Almost all (99%) HIVinfected PWID were also coinfected with HCV. Only 39% of individuals with HCV were also diagnosed with HIV. Prevalence of HCV monoinfection was higher among individuals who had been injecting drugs for more than 2 years as compared with those who had been injecting drugs for less than 2 years (87 vs. 59%). Participants who had been injecting drugs for more than 2 years had a higher prevalence of HIV/HCV coinfection compared with those who had been injecting drugs for less than 2 years (82 vs. 24%).
Correlates for HCV monoinfection
In univariate analysis, being older, being male, ever having a tattoo, having two to five sexual partners in the lifetime, having injected drugs for more than 2 years, injecting drugs at least 2-3 days per week over the past 3 months, a history of drug treatment, and lifetime injection behaviors (ever reusing a needle and syringe, ever sharing diazepam, and ever sharing novocaine) were found to be significantly associated with a higher odds of HCV monoinfection (P < 0.05). Ever sharing a needle was not significantly associated with HCV monoinfection. Those who were currently in a stable relationship or were employed were less likely to have HCV monoinfection ( Table 2) .
In multivariate analysis, models 2, 4, and 5 revealed that ever reusing a syringe and needle [adjusted odds ratio (AOR), 3.23; 95% confidence interval (CI), 2.10-4.98], ever sharing novocaine (AOR, 2.40; 95% CI, 1.57-3.69), and ever sharing diazepam or novocaine (AOR, 2.32; 95% CI, 1.52-3.52) were all significantly associated with a higher odds of HCV monoinfection. Ever sharing diazepam or novocaine remained significant after controlling for potential confounders (models 6 and 7) . In the final model (model 8), the AOR of ever sharing diazepam or novocaine was 2.14 (95% CI, 1.38-3.32) and the AOR of ever reusing a syringe and needle was 3.13 (95% CI, 1.99-4.94). Ever sharing a needle was not statistically significant, with an AOR of 0.65 (95% CI, 0.40-1.05; Table 1 ).
Correlates for HIV/HCV coinfection
Univariate analysis of HIV/HCV coinfection found that being male, ever having a tattoo, having two to five sexual partners in the lifetime, having injected drugs for more than 2 years, injecting drugs at least 2-3 days per week over the past 3 months, a history of drug treatment, and all lifetime injection behaviors (ever sharing a needle, ever reusing a needle and syringe, ever sharing diazepam, ever sharing novocaine) were significantly associated with a higher odds of HCV/HCV coinfection. Individuals in a stable relationship and those who were employed had a relatively lower likelihood of HCV/HCV coinfection compared with those who were not in a stable relationship and who were unemployed.
Multivariate analysis found that, in the first five models, ever sharing a needle (AOR, 1.59; 95% CI, 1.00-2.52), ever reusing a syringe and needle (AOR, 3.94; 95% CI, 2.45-6.34), ever sharing diazepam (AOR, 3.83; 95% CI, 1.60-9.19), ever sharing novocaine (AOR, 2.69; 95% CI, 1.72-4.19), and ever sharing diazepam or novocaine (AOR, 2.90; 95% CI, 1.88-5.50) were all significantly associated with a higher odds of HIV/HCV coinfection. Ever sharing diazepam or novocaine remained significant after controlling for ever sharing a needle (model 6) and ever reusing a syringe and needle (model 7). In the final model (model 8), the AOR of ever sharing diazepam or novocaine was 2.47 (95% CI, 1.57-3.90) and the AOR of ever reusing a syringe and needle was 3.34 (95% CI, 2.02-5.51). Ever sharing a needle was not statistically significant, with an AOR 0.96 (95% CI, 0.58-1.58).
Discussion
In this study, we observed a high prevalence of HCV monoinfection and HIV/HCV coinfection among hard-toreach PWID in Vietnam. These data provide important information on the burden of disease in a high-risk and vulnerable population, which is critical for health resource allocation for the provision of effective treatment and prevention interventions in low-income countries. In the new era of HCV treatment, patients with HCV identified through this study could be potentially treated using oral direct antiviral agents with less adverse effects, less treatment duration, and higher efficacy [23] , which would further reduce the risk of HCV transmission [24] .
In our research, we found that PWID who had ever shared diazepam or novocaine and those who had ever reused a syringe and needle were more likely to have HCV monoinfection and HIV/HCV coinfection. These effects are independent of demographic characteristics and known risk factors and remain of consistent magnitude and significance across all separate models. Of note, there is no substantial difference in correlates between HCV monoinfection and HIV/HCV coinfection. The only difference is that the magnitude of risk for HIV/HCV is slightly higher than that for HCV monoinfection, as people with HIV/HCV coinfection may be exposed to those unsafe injection behaviors to a greater extent.
Both diazepam and novocaine are commonly injected in combination with heroin by PWID in certain parts of the world [17, 25] . One study reported that, in addition to heroin, persons who used drugs were also exposed to a number of other substances in their lifetime in Vietnam, including novocaine (91.6%) and diazepam (24.0%) [26] , which were higher than our findings of an overall 46% using novocaine and 12% using diazepam. Studies also found that PWID may use diazepam or novocaine to augment a suboptimal dose of heroin when they are unable to obtain their full usual dose of heroin. These drugs may also be used to overcome the side effects of heroin withdrawal, as well as to avoid the risk of police arrest, as diazepam and novocaine are significantly cheaper than heroin and are readily and legally purchasable without prescription in pharmacies [26] . PWID who use diazepam or novocaine might be at a particularly high risk, perhaps because they lack money or are in drug withdrawal. This may prompt them to adopt risky injection practices that are not usually practiced in routine injection [27] .
Of note, a history of sharing a needle did not increase the likelihood of HIV and HCV infection in our study. A possible explanation for this is that the measures of sharing may not capture the risk dynamics of injection [28] . We do not know whether individuals followed someone else's injection or passed a needle to others, both of which are associated with different risks for HIV and HCV infection. This analysis also revealed that having multiple sexual partners was associated with lower odds of HIV and HCV infection. This may reflect network stability or less frequent drug use among these individuals, as has been observed previously [29, 30] .
There are several limitations to our study. First, the generalizability of the study's findings is limited to PWID from northern areas of Vietnam. In addition, we were not able to determine causality, as the cross-sectional design precluded temporality of our variables of interest. Third, there may have been some residual under-reporting of lifetime injection or other risk behaviors, as participants may have provided what they perceived to be socially desirable responses. However, the proportion of individuals who reported ever sharing a needle was 28% according to our findings, which is consistent with the range of 27-49% reported by previous studies [16, 31, 32] . Finally, we defined HCV monoinfection as HCV antibody positivity alone. The antibody test for the diagnosis of HCV infection reflects exposure experience rather than the status of chronic infection, as ∼ 15-20% of HCV-exposed individuals may spontaneously clear the virus [20] . Therefore, it is possible that our study may have overestimated the true prevalence of chronic HCV infection.
Our study makes clear the tremendous burden of disease faced by PWID in Vietnam. PWID continue to engage in high-risk sharing behaviors and are adopting new behaviors such as sharing diazepam or novocaine, which appears to be associated with an even higher risk. The advent of a cure for HCV, as well as an effective treatment for HIV, offers real promise for this highly marginalized and vulnerable population. Future interventions should target the specific needs of this population by both addressing prevention of infection and transmission and developing mechanisms for enhancing access to care.
